Uptake of atrial fibrillation screening aiming at stroke prevention: geo-mapping of target population and non-participation

BMC Public Health

Ulf Strömberg²  Mårten Rosenqvist⁴  Anders Holmén³  Johan Engdahl¹ 

[1] Department of Medicine, Halland Hospital, SE-301 85 Halmstad, Sweden;Department of Occupational and Environmental Medicine, Lund University, Sweden;Department of Research and Development, Halland Hospital, SE-301 85 Halmstad, Sweden;Department of Clinical Science and Education, Karolinska Institute, Danderyds Hospital, Stockholm, Sweden

关键词: Stroke prevention;    Participation;    Screening;    Atrial fibrillation;   

Others  :  1161967
DOI  :  10.1186/1471-2458-13-715

 received in 2013-02-05, accepted in 2013-08-01,  发布年份 2013

【 摘 要 】

Background

In a screening study for silent atrial fibrillation (AF), which is a frequent source of cardiac emboli with ischemic stroke, the proportion of non-participants was considerable and their clinical profile differed from the participants’ profile. We intended to geo-map the target population and non-participation in an attempt to understand factors related to screening uptake and, thereby, obtain useful information needed to intervene for improved uptake.

Method

In the municipality of Halmstad, Sweden, all residents born in 1934–1935 were invited to the screening study during April 2010 to February 2012. The total study group included 848 participants and 367 non-participants from 12 parishes. Geo-maps displaying participation, along with target-population-based geo-maps displaying proportion of immigrants and ischemic stroke incidence, were used.

Results

Smoothed non-participation ratios (SmNPR) varied from 0.81 to 1.24 across different parishes (SmNRP = 1 corresponds to the expected participation based on the total study group). Among high risk individuals, the geographical variation was more pronounced (SmNPR range 0.75–1.51). Two parishes with higher share of immigrants and elevated population-based ischemic stroke incidence showed markedly lower participation, particularly among high-risk individuals.

Conclusion

AF screening uptake varied evidently between parishes, particularly among high-risk individuals. Geo-mapping of target population and non-participation yielded useful information needed to intervene for improved screening uptake.

【 授权许可】

   
2013 Engdahl et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991, 22(8):983-988.
• [2]Stewart S, Hart CL, Hole DJ, McMurray JJ: A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002, 113(5):359-364.
• [3]Steg PG, Alam S, Chiang CE, Gamra H, Goethals M, Inoue H, Krapf L, Lewalter T, Merioua I, Murin J, et al.: Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry. Heart 2011, 98(3):195-201.
• [4]Rizos T, Wagner A, Jenetzky E, Ringleb PA, Becker R, Hacke W, Veltkamp R: Paroxysmal atrial fibrillation is more prevalent than persistent atrial fibrillation in acute stroke and transient ischemic attack patients. Cerebrovasc Dis 2011, 32(3):276-282.
• [5]Tagawa M, Takeuchi S, Chinushi M, Saeki M, Taniguchi Y, Nakamura Y, Ohno H, Kitazawa K, Aizawa Y: Evaluating patients with acute ischemic stroke with special reference to newly developed atrial fibrillation in cerebral embolism. Pacing Clin Electrophysiol 2007, 30(9):1121-1128.
• [6]Elijovich L, Josephson SA, Fung GL, Smith WS: Intermittent atrial fibrillation may account for a large proportion of otherwise cryptogenic stroke: a study of 30-day cardiac event monitors. J Stroke Cerebrovasc Dis 2009, 18(3):185-189.
• [7]Stahrenberg R, Weber-Kruger M, Seegers J, Edelmann F, Lahno R, Haase B, Mende M, Wohlfahrt J, Kermer P, Vollmann D, et al.: Enhanced detection of paroxysmal atrial fibrillation by early and prolonged continuous holter monitoring in patients with cerebral ischemia presenting in sinus rhythm. Stroke 2010, 41(12):2884-2888.
• [8]Kirchhof P, Bax J, Blomstrom-Lundquist C, Calkins H, Camm AJ, Cappato R, Cosio F, Crijns H, Diener HC, Goette A, et al.: Early and comprehensive management of atrial fibrillation: proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled ‘research perspectives in atrial fibrillation’. Europace 2009, 11(7):860-885.
• [9]Ericson L, Bergfeldt L, Bjorholt I: Atrial fibrillation: the cost of illness in Sweden. Eur J Health Econ 2011, 12(5):479-487.
• [10]Indredavik B, Rohweder G, Lydersen S: Frequency and effect of optimal anticoagulation before onset of ischaemic stroke in patients with known atrial fibrillation. J Intern Med 2005, 258(2):133-144.
• [11]Leckey R, Aguilar EG, Phillips SJ: Atrial fibrillation and the use of warfarin in patients admitted to an acute stroke unit. Can J Cardiol 2000, 16(4):481-485.
• [12]Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, et al.: Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012, 366(2):120-129.
• [13]Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T, Oeff M, Seipel L, Trappe HJ, Treese N, et al.: Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 2004, 25(16):1385-1394.
• [14]Engdahl J, Andersson L, Mirskaya M, Rosenqvist M: Stepwise screening of atrial fibrillation in a 75-year old population - implications for stroke prevention. Circulation 2013, 127:930-937.
• [15]Hobbs FD, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S, Raftery J, Davies M, Lip G: A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess 2005, 9(40):iii-iv, ix-x, 1–74.
• [16]Tveit A, Abdelnoor M, Enger S, Smith P: Atrial fibrillation and antithrombotic therapy in a 75-year-old population. Cardiology 2008, 109(4):258-262.
• [17]Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ: Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285(22):2864-2870.
• [18]Small area statistics unit [http://www.sahsu.org webcite]
• [19]Beale L, Abellan JJ, Hodgson S, Jarup L: Methodologic issues and approaches to spatial epidemiology. Environ Health Perspect 2008, 116(8):1105-1110.
• [20]Clayton D, Kaldor J: Empirical Bayes estimates of age-standardized relative risks for use in disease mapping. Biometrics 1987, 43(3):671-681.
• [21]Richardson S, Thomson A, Best N, Elliott P: Interpreting posterior relative risk estimates in disease-mapping studies. Environ Health Perspect 2004, 112(9):1016-1025.
• [22]Gimeno García AZ: Factors influencing colorectal cancer screening participation. Gastroenterology Res Pract 2012, 2012:483417.
• [23]Le Breton J, Journy N, Attali C, Le Corvoisier P, Brixi Z, Bastuji-Garin S, Chevreul K: Improving participation in colorectal cancer screening: targets for action. Prev Med 2012, 55(5):488-492.
• [24]Wee LE, Koh GC, Chin RT, Yeo WX, Seow B, Chua D: Socioeconomic factors affecting colorectal, breast and cervical cancer screening in an Asian urban low-income setting at baseline and post-intervention. Prev Med 2012, 55(1):61-67.
• [25]Wanhainen A, Svensjo S, Tillberg M, Mani K, Bjorck M: Abdominal aortic aneurysm screening in Uppsala. Good experiences from the first four years–the rest of Sweden on its way. Lakartidningen 2010, 107(38):2232-2236.
• [26]The bugs project [http://www.mrc-bsu.cam.ac.uk/bugs webcite]
• [27]Soljak M, Samarasundera E, Indulkar T, Walford H, Majeed A: Variations in cardiovascular disease under-diagnosis in England: national cross-sectional spatial analysis. BMC Cardiovasc Disord 2011, 11:12. BioMed Central Full Text